ClinicalTrials.gg
RecruitingNCT05767047Updated Nov 4, 2026

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

A Phase 3 interventional study of Apremilast in Behçet's Disease and Juvenile Psoriatic Arthritis, sponsored by Amgen. Recruiting at 7 sites in 4 countries. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Behcet Syndrome with a site in Turkey — 9 open to participants now, 10 under way, 3 of them phase 3. Behcet Syndrome · Turkey.

Planned enrollment
12th of 16
48 · median 83
Started
2023
with 1 other
Phase 3
5 of 30
3 open now
Registered
20th of 30
by date
Lead sponsor
4 of 30
Amgen

Among the 30 studies in Behcet Syndrome with a site in Turkey, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 20th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

9 of the 30 studies in Behcet Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Behcet Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.

03

Conditions studied

  • Behçet's Disease
  • Juvenile Psoriatic Arthritis

Keywords

  • Oral Ulcers
  • Behçet's Disease
  • Juvenile Psoriatic Arthritis
  • Apremilast
  • AMG 407
  • Otezla
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • / assent obtained
  • Must have completed Week 52 on treatment on core study and must be \< 18 years of age at the time the informed consent document is signed
  • Age and sex specific (BMI) no lower in range than the 5th percentile on Centers for Disease Control (CDC growth chart) at enrollment
  • Willing to adhere to study visit schedule and protocol requirements
  • Must have acceptable benefit/risk for continued treatment with apremilast

Exclusion criteria

Exclusion Criteria:

  • Answer "yes" to any question on C-SSRS at Week 52 visit of core study
  • Scheduled surgery or other interventions that would interrupt study participation
  • Female participants of unwilling to use protocol specified method of during treatment and for 30 days after last dose
  • Female participants planning to become pregnant while on study through 30 days after last dose
  • Female participants of childbearing potential with positive pregnancy test at Week 0
  • Known sensitivity to any products to be administered during dosing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Apremilast

    Participants with a weight between ≥ 12 kg to \< 20 kg will receive apremilast 10 mg BID (twice a day), participants with a weight between ≥ 20 kg to \< 50 kg will receive 20 mg BID, and participants with a weight ≥ 50 kg will receive apremilast 30 mg BID.

    Drug: Apremilast

Interventions

  • Oral tablets or liquid suspension

    Also known as: AMG 407, Otezla, CC-10004

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Adverse events will be classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system.

    Time frame: Up to approximately 4 years

  2. Columbia-Suicide Severity rating Scale (C-SSRS)

    A questionnaire used to assess suicide risk.

    Time frame: Up to approximately 4 years

  3. Tanner Staging

    Tanner Staging of sexual development assessment will be used to assess sexual maturity.

    Time frame: Up to approximately 4 years

  4. Change from Baseline in Body Weight

    Time frame: Up to approximately 4 years

  5. Change from Baseline in Height

    Time frame: Up to approximately 4 years

  6. Change from Baseline in Body Mass Index (BMI)

    Time frame: Up to approximately 4 years

  7. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to approximately 4 years

  8. Number of Participants with Clinically Significant Changes in Laboratory Parameters

    Time frame: Up to approximately 4 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Mar 2036, 155 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Mar 14, 2023
StartActual
Mar 23, 2023
Primary completionEst.
Mar 17, 2036
CompletionEst.
Mar 17, 2036
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05767047
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Mar 23, 2023
Primary completion
Mar 17, 2036 (estimated)
Completion
Mar 17, 2036 (estimated)
Last update
Nov 4, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion